

MORNING AGENDA – PRELIMINARY

7:30 AM	Registration
8:15	Welcome and Introduction <i>Michael S. Saag, MD</i> <i>Jeffrey L. Lennox, MD</i>
8:30	New Approaches for Evaluating the Antiviral Activity of Antiretroviral Drugs <i>Robert F. Siliciano, MD, PhD</i>
9:00	Question-and-Answer Period
9:15	Predicting, Avoiding, and Managing Drug Interactions <i>David J. Back, PhD</i>
9:45	Question-and-Answer Period
10:00	Morning Break
10:30	Management Strategies for Initial Antiretroviral Therapy <i>Donna E. Sweet, MD, MACP</i>
11:00	Question-and-Answer Period
11:10	New Available and Investigational Drugs <i>Jeffrey L. Lennox, MD</i>
11:40	Question-and-Answer Period
11:50	Interpretation of Resistance Tests and Tropism Assays <i>Paul E. Sax, MD</i>
12:20 PM	Question-and-Answer Period
12:30	Summary of Morning Presentations <i>Michael S. Saag, MD</i> <i>Jeffrey L. Lennox, MD</i>
12:35	Hosted Lunch

AFTERNOON AGENDA – PRELIMINARY

- 1:35 **Strategies for Antiretroviral Failure:
Case-based Panel Discussion**
Michael S. Saag, MD
- 2:35 **Question-and-Answer Period**
- 2:45 **Sexually Transmitted Infections in HIV-infected
Individuals**
Laura H. Bachmann, MD, MPH
- 3:15 **Treatment of Hepatitis C Virus Today and
Tomorrow**
David L. Thomas, MD, MPH
- 3:45 **Question-and-Answer Period**
- 3:55 **Summary of Afternoon Presentations**
Michael S. Saag, MD
Jeffrey L. Lennox, MD
- 4:00 **Closing Remarks**